Does MOLNUPIRAVIR Cause Product packaging quantity issue? 65 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 65 reports of Product packaging quantity issue have been filed in association with MOLNUPIRAVIR (LAGEVRIO). This represents 1.4% of all adverse event reports for MOLNUPIRAVIR.
65
Reports of Product packaging quantity issue with MOLNUPIRAVIR
1.4%
of all MOLNUPIRAVIR reports
0
Deaths
1
Hospitalizations
How Dangerous Is Product packaging quantity issue From MOLNUPIRAVIR?
Of the 65 reports, 1 (1.5%) required hospitalization.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MOLNUPIRAVIR. However, 65 reports have been filed with the FAERS database.
What Other Side Effects Does MOLNUPIRAVIR Cause?
Product use issue (706)
No adverse event (614)
Covid-19 (396)
Wrong technique in product usage process (380)
Product use in unapproved indication (296)
Diarrhoea (259)
Accidental underdose (207)
Product use complaint (206)
Rash (200)
Underdose (183)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which MOLNUPIRAVIR Alternatives Have Lower Product packaging quantity issue Risk?
MOLNUPIRAVIR vs MOLSIDOMINE
MOLNUPIRAVIR vs MOMELOTINIB
MOLNUPIRAVIR vs MOMETASONE
MOLNUPIRAVIR vs MOMETASONE FUROATE
MOLNUPIRAVIR vs MOMETASONE FUROATE\OLOPATADINE